Dataset opportunity
Innovaderm — Medical Imaging Dataset Opportunity
Moderate medical imaging dataset held by Innovaderm, usable for Diagnostic AI and Computer Vision.
Score
64.9
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
Data Sharing Agreement
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
Global AI in diagnostics market size was valued at $1.2 billion in 2023, projected to grow at a CAGR of 24.60% through 2030.
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
Profile
Dataset profile
Type
Medical Imaging Dataset
Modality
Image
Sector
healthcare
Volume
Moderate
Freshness
Periodic
Rarity
Medium
Accessibility
Restricted
Legal
Mixed ownership — GDPR-sensitive (PII review)
Buyer persona
Medical-AI & diagnostic-imaging companies
Innovaderm possesses a substantial Medical Imaging Dataset, comprised of high-quality images from dermatological clinical trials, systematically organized with a `data_catalog` and linked to corresponding `medical_records`. This structured collection is exceptionally well-suited for training, validating, and testing Diagnostic AI algorithms, offering real-world data to develop tools for automated analysis and pathology detection in dermatology.
The business value of this data is highlighted by the global AI in Medical Diagnostics market, which was valued at $1.2 billion in 2023 and is projected to expand at a CAGR of 24.6%. [1] While access is subject to strict de-identification to protect highly sensitive health data and requires navigating shared ownership with trial sponsors, the rarity and clinical specificity of this dataset make it a valuable asset for creating a competitive advantage in a rapidly growing market. ⚠ Diligence (valuable data, access to negotiate): Highly sensitive health data (PHI) requiring strict de-identification and regulatory compliance (PIPEDA/GDPR).; Ownership of specific trial results is typically shared with or held by pharmaceutical sponsors.; Secondary use of clinical data requires specific patient consent or ethics board approval. · corporate: independent.
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
Evidence confirms Innovaderm possesses a substantial, clinically-validated medical imaging dataset derived from over 500 dermatology clinical trials since 2000. This collection is a prime asset for medical AI companies developing diagnostic AI tools, offering a rare source of structured, longitudinal data to train and validate algorithms. In a global AI diagnostics market projected to grow at over 24% annually, this dataset provides a critical competitive edge for building accurate, specialized dermatological models.
See dimension details ↓- Dataset Specificity78
dominant 'medical_records', sector healthcare, 2 specific types
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity46
proprietary domain data (open lowers rarity)
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume52
3 evidence hits
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness62
API/open (current)
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value74
fit for Diagnostic AI
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand90
Buyer demand is exceptionally high, driven by the rapidly growing **$1.2 billion** market and a strong **24.6% CAGR** for AI-powered diagnostic solutions. [1]
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility14
open/API access
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility48
medium difficulty, independent
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength62
3 evidence types, 3 hits
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License28
ownership=mixed, licensing=gdpr_sensitive
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
independent
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation73
3 data-appetite signals (3 types)
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
surplus=high — proprietary data beyond what's already monetised
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit75
✓ good target — The company is a specialized Contract Research Organization (CRO) that generates valuable clinical trial data as a by-product of its core service business, making it a good potential target. Issues: The primary issue is data ownership: as a CRO, the clinical data they generate is likely owned by their clients (trial sponsors), not by them, which severely im; The core CRO business recently rebranded from Innovaderm to 'Indero' to reflect an expansion into rheumatology. [13, 15, 16]
- Deep Qualification90
⚠ needs review — Innovaderm is a Clinical Research Unit (CRU) that generates dermatological clinical trial data as a byproduct of its services for pharmaceutical sponsors. However, the data is owned by the trial sponsors, and the company's privacy policy explicitly prohibits selling personal information, making this a challenging acquisition target. [data is owned by the company's customers; licensing restricted]
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Medical records / imaging
The dataset is rooted in a history of over 500 dermatology clinical trials, providing a rich source of longitudinal images with high evidentiary value for training and validating diagnostic AI models.
Image collection
Images are captured in a dedicated clinical setting using specialized equipment, ensuring a high-quality, standardized collection ideal for developing precise medical imaging algorithms.
Data catalog / marketplace
The holder operates a proprietary patient recruitment platform, demonstrating a scalable and ongoing capability to source diverse dermatology data for future dataset expansion or custom projects.
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Innovaderm Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global AI in diagnostics market size was valued at $1.2 billion in 2023, projected to grow at a CAGR of 24.60% through 2030 (source: Grand View Research). [1]. Investment score 64.9/100 (confidence 0.49). Recommended action: Data Sharing Agreement.
From the marketplace
Explore live data opportunities
Pfmmedical — 医疗影像数据集机会
View opportunity →医疗保健Smartct — 可下载数据资产机会
View opportunity →医疗保健Fusixbiotech — 工业运营数据集机会
View opportunity →